Mepolizumab: Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis

Lota Ozola; Elīna Aleksejeva; Diāna Stoldere; Zane Dāvidsone; Ruta Šantere; Ineta Grantiņa; Ieva Cīrule; Alvils Krams

doi:10.1002/ppul.26249

Mepolizumab: Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis

Lota Ozola, Elīna Aleksejeva, Diāna Stoldere (Coresponding Author), Zane Dāvidsone, Ruta Šantere, Ineta Grantiņa, Ieva Cīrule, Alvils Krams

Department of Paediatrics

Research output: Contribution to journal › Letter › peer-review

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome) is classified as an antineutrophil cytoplasmic antibody (ANCA)-associated small vessel vasculitis. It is a multisystem disorder and can affect every organ system. EGPA is a rare disease, with an estimated prevalence of 1/70,000–100,000 in Europe. As its onset usually occurs in adulthood, data from pediatric patients are limited. We present here a very rare practical EGPA clinical case involving a pediatric patient. Presently, data on mepolizumab usage in pediatric patients are limited, with only a few case reports published.

Original language	English
Pages (from-to)	973-979
Journal	Pediatric Pulmonology
Volume	58
Issue number	3
DOIs	https://doi.org/10.1002/ppul.26249
Publication status	Published - Mar 2023

Keywords*

mepolizumab in pediatrics
pediatric EGPA
small vessel vasculitis

Field of Science*

3.2 Clinical medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.1002/ppul.26249

Cite this

@article{a76d6b67775f4689a653f30588d9f8da,

title = "Mepolizumab: Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis",

abstract = "Eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome) is classified as an antineutrophil cytoplasmic antibody (ANCA)-associated small vessel vasculitis. It is a multisystem disorder and can affect every organ system. EGPA is a rare disease, with an estimated prevalence of 1/70,000–100,000 in Europe. As its onset usually occurs in adulthood, data from pediatric patients are limited. We present here a very rare practical EGPA clinical case involving a pediatric patient. Presently, data on mepolizumab usage in pediatric patients are limited, with only a few case reports published.",

keywords = "mepolizumab in pediatrics, pediatric EGPA, small vessel vasculitis",

author = "Lota Ozola and Elīna Aleksejeva and Diāna Stoldere and Zane Dāvidsone and Ruta {\v S}antere and Ineta Grantiņa and Ieva Cīrule and Alvils Krams",

note = "Publisher Copyright: {\textcopyright} 2022 Wiley Periodicals LLC.",

year = "2023",

month = mar,

doi = "10.1002/ppul.26249",

language = "English",

volume = "58",

pages = "973--979",

journal = "Pediatric Pulmonology",

issn = "8755-6863",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - Mepolizumab

T2 - Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis

AU - Ozola, Lota

AU - Aleksejeva, Elīna

AU - Stoldere, Diāna

AU - Dāvidsone, Zane

AU - Šantere, Ruta

AU - Grantiņa, Ineta

AU - Cīrule, Ieva

AU - Krams, Alvils

PY - 2023/3

Y1 - 2023/3

N2 - Eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome) is classified as an antineutrophil cytoplasmic antibody (ANCA)-associated small vessel vasculitis. It is a multisystem disorder and can affect every organ system. EGPA is a rare disease, with an estimated prevalence of 1/70,000–100,000 in Europe. As its onset usually occurs in adulthood, data from pediatric patients are limited. We present here a very rare practical EGPA clinical case involving a pediatric patient. Presently, data on mepolizumab usage in pediatric patients are limited, with only a few case reports published.

AB - Eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome) is classified as an antineutrophil cytoplasmic antibody (ANCA)-associated small vessel vasculitis. It is a multisystem disorder and can affect every organ system. EGPA is a rare disease, with an estimated prevalence of 1/70,000–100,000 in Europe. As its onset usually occurs in adulthood, data from pediatric patients are limited. We present here a very rare practical EGPA clinical case involving a pediatric patient. Presently, data on mepolizumab usage in pediatric patients are limited, with only a few case reports published.

KW - mepolizumab in pediatrics

KW - pediatric EGPA

KW - small vessel vasculitis

UR - http://www.scopus.com/inward/record.url?scp=85143970649&partnerID=8YFLogxK

U2 - 10.1002/ppul.26249

DO - 10.1002/ppul.26249

M3 - Letter

C2 - 36404638

AN - SCOPUS:85143970649

SN - 8755-6863

VL - 58

SP - 973

EP - 979

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

IS - 3

ER -

Mepolizumab: Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis

Abstract

Keywords*

Field of Science*

Publication Type*

Access to Document

Other files and links

Fingerprint

Cite this